Review Article: The Role of Molecular Pathological Epidemiology in the Study of Neoplastic and Non-neoplastic Diseases in the Era of Precision Medicine

Molecular pathology diagnostics to subclassify diseases based on pathogenesis are increasingly common in clinical translational medicine. Molecular pathological epidemiology (MPE) is an integrative transdisciplinary science based on the unique disease principle and the disease continuum theory. While it has been most commonly applied to research on breast, lung, and colorectal cancers, MPE can investigate etiologic heterogeneity in non-neoplastic diseases, such as cardiovascular diseases, obesity, diabetes mellitus, drug toxicity, and immunity-related and infectious diseases. This science can enhance causal inference by linking putative etiologic factors to specific molecular biomarkers as outcomes. Technological advances increasingly enable analyses of various -omics, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, metagenomics, microbiome, immunomics, interactomics, etc. Challenges in MPE include sample size limitations (depending on availability of biospecimens or biomedical/radiological imaging), need for rigorous validation of molecular assays and study findings, and paucities of interdisciplinary experts, education programs, international forums, and standardized guidelines. To address these challenges, there are ongoing efforts such as multidisciplinary consortium pooling projects, the International Molecular Pathological Epidemiology Meeting Series, and the Strengthening the Reporting of Observational Studies in Epidemiology-MPE guideline project. Efforts should be made to build biorepository and biobank networks, and worldwide population-based MPE databases. These activities match with the purposes of the Big Data to Knowledge (BD2K), Genetic Associations and Mechanisms in Oncology (GAME-ON), and Precision Medicine Initiatives of the United States National Institute of Health. Given advances in biotechnology, bioinformatics, and computational/systems biology, there are wide open opportunities in MPE to contribute to public health.

[1]  Shuji Ogino,et al.  Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.

[2]  S. Ogino,et al.  Molecular classification and correlates in colorectal cancer. , 2008, The Journal of molecular diagnostics : JMD.

[3]  S. Ogino,et al.  Aspirin Use and Survival After Diagnosis of Colorectal Cancer , 2009 .

[4]  S. Ogino,et al.  Aspirin Use and Survival After Diagnosis of Colorectal Cancer , 2009 .

[5]  D. Spiegelman,et al.  A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. , 2009, Gastroenterology.

[6]  N. Chatterjee,et al.  Analysis of cohort studies with multivariate and partially observed disease classification data. , 2010, Biometrika.

[7]  Shuji Ogino,et al.  Editorial Lifestyle Factors and Microsatellite Instability in Colorectal Cancer: the Evolving Field of Molecular Pathological Epidemiology , 2022 .

[8]  E. Giovannucci,et al.  Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field , 2010, Gut.

[9]  J. Meyerhardt,et al.  Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. , 2011, Journal of the National Cancer Institute.

[10]  R. Goldbohm,et al.  Body Size, Physical Activity and Risk of Colorectal Cancer with or without the CpG Island Methylator Phenotype (CIMP) , 2011, PloS one.

[11]  P. Febbo,et al.  NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  E. Giovannucci,et al.  Statin Use and Colorectal Cancer Risk According to Molecular Subtypes in Two Large Prospective Cohort Studies , 2011, Cancer Prevention Research.

[13]  Martha L. Slattery,et al.  CpG Island Methylation in Colorectal Cancer: Past, Present and Future , 2011, Pathology research international.

[14]  Y. Sakamoto,et al.  Pyrosequencing Assay to Measure LINE-1 Methylation Level in Esophageal Squamous Cell Carcinoma , 2012, Annals of Surgical Oncology.

[15]  G. Dranoff,et al.  Cancer immunology—analysis of host and tumor factors for personalized medicine , 2011, Nature Reviews Clinical Oncology.

[16]  Charles J. Kahi,et al.  Serrated Lesions of the Colorectum: Review and Recommendations From an Expert Panel , 2012, The American Journal of Gastroenterology.

[17]  J. Cerhan,et al.  Postmenopausal Hormone Therapy and Colorectal Cancer Risk in Relation to Somatic KRAS Mutation Status among Older Women , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[18]  T. Sellers,et al.  Integrative cancer epidemiology--the next generation. , 2012, Cancer discovery.

[19]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[20]  Ronglai Shen,et al.  Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers , 2012, Clinical Cancer Research.

[21]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[22]  R. Luben,et al.  Dietary, lifestyle and clinicopathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPIC‐Norfolk study , 2012, The Journal of pathology.

[23]  J. Koshiol,et al.  Can tissue-based immune markers be used for studying the natural history of cancer? , 2012, Annals of epidemiology.

[24]  R. Ali,et al.  Aspirin as adjuvant therapy for colorectal cancer—reinterpreting paradigms , 2012, Nature Reviews Clinical Oncology.

[25]  Shuji Ogino,et al.  Colorectal cancer: a tale of two sides or a continuum? , 2012, Gut.

[26]  R. Goldbohm,et al.  Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: a pooled analysis. , 2012, International journal of epidemiology.

[27]  P. A. van den Brandt,et al.  The CpG island methylator phenotype in colorectal cancer: progress and problems. , 2012, Biochimica et biophysica acta.

[28]  F. Grizzi,et al.  Adaptive and Innate Immunity, Non Clonal Players in Colorectal Cancer Progression , 2012 .

[29]  Shuji Ogino,et al.  How many molecular subtypes? Implications of the unique tumor principle in personalized medicine , 2012, Expert review of molecular diagnostics.

[30]  Y. Pawitan,et al.  Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X , 2012, Modern Pathology.

[31]  Andrew H. Beck,et al.  Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. , 2012, American journal of epidemiology.

[32]  Levi Waldron,et al.  Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum , 2012, Gut.

[33]  E. Giovannucci,et al.  Commentary: Lifestyle factors and colorectal cancer microsatellite instability--molecular pathological epidemiology science, based on unique tumour principle. , 2012, International journal of epidemiology.

[34]  J. Hardwick,et al.  Cholesterol metabolism and colorectal cancers. , 2012, Current opinion in pharmacology.

[35]  J. Swinnen,et al.  Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. , 2013, Progress in lipid research.

[36]  Nita Ahuja,et al.  The CpG island methylator phenotype: what's in a name? , 2013, Cancer research.

[37]  Alexander Meissner,et al.  Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease , 2013, Modern Pathology.

[38]  N. Cho,et al.  Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location , 2013, British Journal of Cancer.

[39]  S. Ogino,et al.  The merits of subtyping obesity: one size does not fit all. , 2013, JAMA.

[40]  P. A. van den Brandt,et al.  The mTOR Pathway and the Role of Energy Balance Throughout Life in Colorectal Cancer Etiology and Prognosis: Unravelling Mechanisms Through a Multidimensional Molecular Epidemiologic Approach , 2013, Current Nutrition Reports.

[41]  Reiko Nishihara,et al.  Long-term colorectal-cancer incidence and mortality after lower endoscopy. , 2013, The New England journal of medicine.

[42]  F. Bazzoli,et al.  Molecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention , 2013, International journal of molecular sciences.

[43]  Kjetil Søreide,et al.  Molecular Pathways and Cellular Metabolism in Colorectal Cancer , 2013, Digestive Surgery.

[44]  S. Kaufmann,et al.  Diagnostic biomarkers are hidden in the infected host’s epigenome , 2013, Expert review of molecular diagnostics.

[45]  R. Kaliaperumal,et al.  Conventional and nanotechniques for DNA methylation profiling. , 2013, The Journal of molecular diagnostics : JMD.

[46]  Abstract CN06-01: Molecular pathological epidemiology (MPE): Overview of its paradigm and wide applicability even without tumor tissue , 2013 .

[47]  E. Livingston,et al.  New insights on bariatric surgery outcomes. , 2013, JAMA.

[48]  F. Sinicrope,et al.  Aspirin and Colorectal Cancer: Back to the Future , 2013, Clinical Cancer Research.

[49]  Aung Ko Win,et al.  Family History of Colorectal Cancer in BRAF p.V600E-Mutated Colorectal Cancer Cases , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[50]  J. Potter,et al.  Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. , 2013, Cancer research.

[51]  W. Willett,et al.  Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. , 2013, American journal of epidemiology.

[52]  C. Carlson,et al.  Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. , 2013, International journal of molecular epidemiology and genetics.

[53]  N. Ajami,et al.  Potential role of gastrointestinal microbiota composition in prostate cancer risk , 2013, Infectious Agents and Cancer.

[54]  Aung Ko Win,et al.  Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features , 2013, Modern Pathology.

[55]  The role of epidemiology in the era of molecular epidemiology and genomics: Summary of the 2013 AJE-sponsored Society of Epidemiologic Research Symposium. , 2013, American journal of epidemiology.

[56]  D. Kerr,et al.  Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  A. A. de Araújo,et al.  Lifestyle and family history influence cancer prognosis in Brazilian individuals. , 2013, Pathology, research and practice.

[58]  K. Jirström,et al.  Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability , 2014, BMC Cancer.

[59]  M. Kloor,et al.  Body Mass Index and Microsatellite Instability in Colorectal Cancer: A Population-based Study , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[60]  M. Ribeiro,et al.  MGMT and MLH1 methylation in Helicobacter pylori-infected children and adults. , 2013, World journal of gastroenterology.

[61]  M. Woods,et al.  Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype , 2014, British Journal of Cancer.

[62]  N. Shaheen Editorial: What Is Behind the Remarkable Increase in Esophageal Adenocarcinoma? , 2014, The American Journal of Gastroenterology.

[63]  S. Thibodeau,et al.  Establishment of the Cancer Prevention Study II Nutrition Cohort Colorectal Tissue Repository , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[64]  J. Meyerhardt,et al.  Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology , 2014, Oncogene.

[65]  Thomas Mikeska,et al.  DNA Methylation Biomarkers: Cancer and Beyond , 2014, Genes.

[66]  R. Bostick,et al.  Challenges and Opportunities in International Molecular Cancer Prevention Research: An ASPO Molecular Epidemiology and the Environment and International Cancer Prevention Interest Groups Report , 2014, Cancer Epidemiology, Biomarkers and Prevention.

[67]  R. van Winkel Aetiological stratification as a conceptual framework for gene-by-environment interaction research in psychiatry , 2014, Epidemiology and Psychiatric Sciences.

[68]  Seth D. Crockett,et al.  Risk Factors for Serrated Polyps of the Colorectum , 2014, Digestive Diseases and Sciences.

[69]  A. L. Cisyk,et al.  Characterizing the prevalence of chromosomal instability in interval colorectal cancer , 2014 .

[70]  Han Wu,et al.  Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis , 2014, Gut.

[71]  P. A. van den Brandt,et al.  Body Size, Physical Activity, Early-Life Energy Restriction, and Associations with Methylated Insulin-like Growth Factor–Binding Protein Genes in Colorectal Cancer , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[72]  R. Malekzadeh,et al.  Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. , 2014, World journal of gastroenterology.

[73]  F. Coppedè The role of epigenetics in colorectal cancer , 2014, Expert review of gastroenterology & hepatology.

[74]  E. Giovannucci,et al.  Progress and Opportunities in Molecular Pathological Epidemiology of Colorectal Premalignant Lesions , 2014, The American Journal of Gastroenterology.

[75]  Hiromu Suzuki,et al.  Biological significance of the CpG island methylator phenotype. , 2014, Biochemical and biophysical research communications.

[76]  Vojtech Huser,et al.  Developing genomic knowledge bases and databases to support clinical management: current perspectives , 2014, Pharmacogenomics and personalized medicine.

[77]  Witvliet Mi World Health Survey: A Useful Yet Underutilized Global Health Data Source , 2014 .

[78]  R. Sinha,et al.  A prospective study of serum metabolites and colorectal cancer risk , 2014, Cancer.

[79]  R. Wolff,et al.  An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer. , 2014, Cancer epidemiology.

[80]  E. Giovannucci,et al.  Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of 15-Hydroxyprostaglandin Dehydrogenase (HPGD) , 2014, Science Translational Medicine.

[81]  E. Giovannucci,et al.  Environmental Exposure and Tumor Heterogeneity in Colorectal Cancer Risk and Outcomes , 2014, Current Colorectal Cancer Reports.

[82]  K. Jirström,et al.  Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker , 2014, Diagnostic Pathology.

[83]  E. Jordanova,et al.  Molecular Backgrounds of ERAP1 Downregulation in Cervical Carcinoma , 2015, Analytical cellular pathology.

[84]  V. Seshan,et al.  Identifying Etiologically Distinct Sub-Types of Cancer: A Demonstration Project Involving Breast Cancer , 2015, Cancer Medicine.

[85]  C. Huttenhower,et al.  Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. , 2015, JAMA oncology.

[86]  Aung Ko Win,et al.  Association between Body Mass Index and Mortality for Colorectal Cancer Survivors: Overall and by Tumor Molecular Phenotype , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[87]  J. Cerhan,et al.  Associations between Environmental Exposures and Incident Colorectal Cancer by ESR2 Protein Expression Level in a Population-Based Cohort of Older Women , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[88]  Andrew H. Beck,et al.  Proceedings of the third international molecular pathological epidemiology (MPE) meeting , 2017, Cancer Causes & Control.

[89]  S. Ogino,et al.  A Meta-Regression Method for Studying Etiological Heterogeneity Across Disease Subtypes Classified by Multiple Biomarkers. , 2015, American journal of epidemiology.

[90]  K. Sheahan,et al.  Estrogen Receptors and Their Implications in Colorectal Carcinogenesis , 2015, Front. Oncol..

[91]  E. Giovannucci,et al.  Marine ω-3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability. , 2015, Journal of the National Cancer Institute.

[92]  C. Ulrich,et al.  Translational Cancer Research: Balancing Prevention and Treatment to Combat Cancer Globally , 2014, Journal of the National Cancer Institute.

[93]  E. Giovannucci,et al.  Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status , 2015, Gut.

[94]  Jun Yu,et al.  Promoter Hypermethylation of Tumour Suppressor Genes as Potential Biomarkers in Colorectal Cancer , 2015, International journal of molecular sciences.

[95]  K. Søreide,et al.  Cellular metabolism in colorectal carcinogenesis: Influence of lifestyle, gut microbiome and metabolic pathways. , 2015, Cancer letters.

[96]  Łukasz Szylberg,et al.  Serrated Polyps and Their Alternative Pathway to the Colorectal Cancer: A Systematic Review , 2015, Gastroenterology research and practice.

[97]  I. Kawachi,et al.  Lifecourse epidemiology and molecular pathological epidemiology. , 2015, American Journal of Preventive Medicine.

[98]  Peter W. Laird,et al.  Association of the Colorectal CpG Island Methylator Phenotype with Molecular Features, Risk Factors, and Family History , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[99]  C. Chua,et al.  Addressing the needs of colorectal cancer survivors: current strategies and future directions , 2015, Expert review of anticancer therapy.

[100]  Andrew H. Beck,et al.  Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression , 2015, Modern Pathology.